Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.61 +1.3%	$1.44	$1.05 ▼ $5.17	$174.33M	0.38	1.18 million shs	650,344 shs
DERM Journey Medical	$7.19 -1.5%	$7.05	$3.54 ▼ $8.25	$167.50M	0.8	91,814 shs	64,122 shs
ITRM Iterum Therapeutics	$0.92 -6.5%	$0.98	$0.81 ▼ $3.02	$36.66M	2.79	1.09 million shs	1.81 million shs
SPRO Spero Therapeutics	$2.37 -4.4%	$2.26	$0.51 ▼ $3.22	$132.51M	1.33	1.24 million shs	969,965 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+2.55%	+13.38%	+41.23%	+21.97%
DERM Journey Medical	0.00%	+0.56%	+13.23%	+15.04%	+25.48%
ITRM Iterum Therapeutics	0.00%	-18.88%	-8.34%	-15.13%	-28.95%
SPRO Spero Therapeutics	0.00%	-15.66%	-19.39%	+214.24%	+60.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	1.8018 of 5 stars	3.6	1.0	0.0	1.1	1.7	0.6
DERM Journey Medical	2.2843 of 5 stars	3.5	1.0	0.0	2.8	1.7	0.6
ITRM Iterum Therapeutics	1.3923 of 5 stars	3.5	3.0	0.0	0.6	0.0	0.0
SPRO Spero Therapeutics	3.4375 of 5 stars	3.3	3.0	4.7	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	441.26% Upside
DERM Journey Medical	3.00	Buy	$9.50	32.13% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	881.89% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	110.97% Upside

Current Analyst Ratings Breakdown

Latest ITRM, SPRO, ACRS, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/15/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.31	N/A	N/A	$1.44 per share	1.12
DERM Journey Medical	$56.13M	2.98	N/A	N/A	$0.91 per share	7.90
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.15) per share	N/A
SPRO Spero Therapeutics	$47.98M	2.76	N/A	N/A	$0.85 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-14.76%	-52.03%	-11.28%	8/11/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-71.37%	8/13/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest ITRM, SPRO, ACRS, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	DERM Journey Medical	-$0.06	N/A	N/A	N/A	$14.93 million	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/4/2025	Q2 2025	SPRO Spero Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
DERM Journey Medical	1.07	1.34	1.03
ITRM Iterum Therapeutics	N/A	3.72	3.58
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DERM Journey Medical	7.25%
ITRM Iterum Therapeutics	9.21%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
DERM Journey Medical	15.03%
ITRM Iterum Therapeutics	9.20%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
ITRM Iterum Therapeutics	10	40.00 million	36.32 million	Not Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

ITRM, SPRO, ACRS, and DERM Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?

July 1, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street Zen

June 21, 2025 | marketbeat.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 29, 2025 | finanznachrichten.de

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Smart Investors Are Watching These 3 Undervalued Stocks
By Gabriel Osorio-Mazilli | July 12, 2025
View Smart Investors Are Watching These 3 Undervalued Stocks

ITRM, SPRO, ACRS, and DERM Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.61 +0.02 (+1.26%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.05 (-3.11%)

As of 07/18/2025 07:44 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Journey Medical NASDAQ:DERM

$7.19 -0.11 (-1.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.20 +0.00 (+0.07%)

As of 07/18/2025 04:06 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Iterum Therapeutics NASDAQ:ITRM

$0.92 -0.06 (-6.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.92 +0.00 (+0.37%)

As of 07/18/2025 07:54 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Spero Therapeutics NASDAQ:SPRO

$2.37 -0.11 (-4.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.34 -0.03 (-1.43%)

As of 07/18/2025 07:50 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time